- Home
- KPTI
as 10-24-2025 3:56pm EST
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | NEWTON |
| Market Cap: | 102.4M | IPO Year: | 2013 |
| Target Price: | $31.71 | AVG Volume (30 days): | 302.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -14.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.51 - $16.95 | Next Earning Date: | 11-11-2025 |
| Revenue: | $137,269,000 | Revenue Growth: | -5.77% |
| Revenue Growth (this year): | 3.4% | Revenue Growth (next year): | 9.69% |
Stock Insider Trading Activity of Karyopharm Therapeutics Inc. (KPTI)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Abate Kristin | KPTI | Chief Accounting Officer | Oct 1 '25 | Sell | $6.30 | 362 | $2,279.15 | 10,046 | |
| Poulton Stuart | KPTI | EVP, Chief Development Officer | Sep 15 '25 | Sell | $6.43 | 401 | $2,578.43 | 27,710 | |
| Cheng Sohanya Roshan | KPTI | EVP & Chief Commercial Officer | Sep 15 '25 | Sell | $6.43 | 325 | $2,089.75 | 35,856 | |
| Paulson Richard A. | KPTI | President and CEO | Sep 15 '25 | Sell | $6.43 | 1,257 | $8,082.51 | 84,046 | |
| Mano Michael | KPTI | SVP, General Counsel&Secretary | Sep 15 '25 | Sell | $6.43 | 234 | $1,504.62 | 21,425 | |
| Rangwala Reshma | KPTI | EVP & Chief Medical Officer | Sep 15 '25 | Sell | $6.43 | 408 | $2,623.44 | 29,390 | |
| Abate Kristin | KPTI | Chief Accounting Officer | Sep 15 '25 | Sell | $6.43 | 23 | $147.89 | 10,046 | |
| Abate Kristin | KPTI | Chief Accounting Officer | Sep 3 '25 | Sell | $6.78 | 12 | $81.36 | 10,046 |
Latest Karyopharm Therapeutics Inc. News
KPTI Breaking Stock News: Dive into KPTI Ticker-Specific Updates for Smart Investing
Zacks
9 days ago
Karyopharm Therapeutics (KPTI)'s Technical Outlook is Bright After Key Golden Cross
Simply Wall St.
13 days ago
How Recent Developments Are Shaping the Karyopharm Therapeutics Investment Story
MT Newswires
13 days ago
Sector Update: Health Care Stocks Edge Lower Late Afternoon
MT Newswires
13 days ago
Sector Update: Health Care
MT Newswires
13 days ago
Karyopharm Therapeutics Shares Rise After HC Wainwright Upgrade
MT Newswires
14 days ago
HC Wainwright Upgrades Karyopharm Therapeutics to Buy From Neutral, $15 Price Target
PR Newswire
19 days ago
Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis
PR Newswire
25 days ago
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compare KPTI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KPTI Karyopharm Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.